Indexado en

MAG Enlace externo Enlace externo

Licencia y uso

Citaciones

Altmetrics

Análisis de autorías institucional

Vera Mendoza, Maria IsabelAutor o Coautor

Compartir

Eluxadoline en el tratamiento del síndrome de intestino irritable con predominio de diarrea: Punto de vista SEPD

Publicado en:REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS. 109 (11): 788-794-794 - 2017-01-01 109(11), DOI: 10.17235/reed.2017.5078/2017

Autores: Vera Mendoza, María Isabel; Júdez Gutiérrez, Francisco Javier

Afiliaciones

Resumen

Functional gut disorders, including diarrhea-predominant irritable bowel syndrome, are highly prevalent conditions worldwide that significantly impact health economy and patient quality of life, yet lacking fully satisfactory therapeutic options. These circumstances fostered research on various molecules with more specific therapeutic targets, including opioid receptors. Eluxadoline (Allergan's Vibercy® in the USA, Truberzi® in Europe) is a locally-acting mixed mu- and kappa-opioid receptor agonist, and delta-opioid receptor antagonist, that was licensed in 2015 by the Food and Drug Administration (FDA) and in 2016 by the European Medicines Agency (EMA) for use in diarrhea-predominant irritable bowel syndrome. Eluxadoline provides, with advantage over the current standard of care, control of both stool consistency and abdominal pain, good tolerability in most cases, and improved quality of life, hence it deserves consideration when approaching a patient with this disorder. As with any recently approved therapy, adequate pharmacovigilance is to be expected, as well as studies to inform on different scenarios such as on-demand therapy, loss of response assessment, use as rescue therapy for other molecules, and cost-effectiveness, to further characterize and more accurately position eluxadoline within the therapeutic spectrum.

Palabras clave